Syntara (ASX: SNT) has just announced a positive outcome from its in‑person Type C meeting with the US FDA, giving the green light to the Phase 2b trial design for its lead asset, amsulostat, in myelofibrosis.
The attached video breaks down what this FDA feedback actually means for amsulostat, how it supports late‑stage development and partnering discussions, and why 2026 is shaping up as a pivotal year for Syntara shareholders.
Highlights
- Positive FDA Type C meeting for amsulostat in myelofibrosis and support for the overall Phase 2b design and development plan.
- Planned ~100‑patient, double‑blind, placebo‑controlled Phase 2b study, with amsulostat added to standard JAK inhibition.
- Primary endpoint: 50% reduction in total symptom score (TSS50) after 9 months of treatment, providing a clear path into late‑stage clinical development.
- Formal FDA alignment de‑risks the regulatory pathway, strengthens amsulostat’s value ahead of potential partnering and reinforces its differentiated status, with Fast Track and Orphan Drug Designations already in place.
- Additional upside from two ongoing MDS studies and other 2026 clinical catalysts, supporting a validated strategy, clearer path to value creation, and multiple near‑term catalysts for shareholders.
- CEO perspective: CEO Gary Phillips describes amsulostat as a potential breakthrough therapy for MF patients who have limited options, and emphasises that multiple clinical milestones across amsulostat, MDS, iRBD and scarring make 2026 a pivotal year for the company.